These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8167386)

  • 21. Interleukin-1-beta, tumour necrosis factor-alpha, islet-cell antibody, and insulin secretion in children with thalassemia major on long-term blood transfusion.
    el Nawawy A; Soliman AT; el Azzouni O; Abbassy AA; Massoud MN; Marzouk S; Ibrahim F; Helal L
    J Trop Pediatr; 1996 Dec; 42(6):362-4. PubMed ID: 9009565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cytokines release related to cardiopulmonary bypass in patients with prosthetic valve replacement].
    Xiao X; Zhang C; Yang H; Zhao Z; Du X; Li Y; Wei D; Zhang P
    Hua Xi Yi Ke Da Xue Xue Bao; 1998 Mar; 29(1):74-8. PubMed ID: 10683986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monocyte function in IDDM patients and healthy individuals.
    Mølvig J; Pociot F; Baek L; Worsaae H; Dall Wogensen L; Christensen P; Staub-Nielsen L; Mandrup-Poulsen T; Manogue K; Nerup J
    Scand J Immunol; 1990 Sep; 32(3):297-311. PubMed ID: 1698309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial and venous cytokine response to cardiopulmonary bypass for low risk CABG and relation to hemodynamics.
    Deng MC; Wiedner M; Erren M; Möllhoff T; Assmann G; Scheld HH
    Eur J Cardiothorac Surg; 1995; 9(1):22-9. PubMed ID: 7727142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional cytokine changes following OKT3 induction for islet cell transplantation in humans: early increase in portal and systemic levels of interleukin-6 and tumor necrosis factors.
    Burke GW; Alejandro R; Cirocco R; Nery J; Mintz D; Miller J
    Transplant Proc; 1992 Jun; 24(3):962-4. PubMed ID: 1604687
    [No Abstract]   [Full Text] [Related]  

  • 26. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes.
    Mohamed-Ali V; Armstrong L; Clarke D; Bolton CH; Pinkney JH
    J Intern Med; 2001 Nov; 250(5):415-21. PubMed ID: 11887976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr.
    Snorgaard O; Lassen LH; Binder C
    Diabetes Care; 1992 Aug; 15(8):1009-13. PubMed ID: 1505301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical efficacy and T-lymphocyte subset, serum interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin-2(IL-2) levels on treatment of chronic aplastic anemia patients by shenfu injection combined with stanozol and cyclosporin A].
    Wang SY; Wei YF; Du HL; Ren LL; Li SH
    Zhongguo Zhong Yao Za Zhi; 2005 Mar; 30(5):383-5. PubMed ID: 15806975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals.
    Netea MG; Hancu N; Blok WL; Grigorescu-Sido P; Popa L; Popa V; van der Meer JW
    Cytokine; 1997 Apr; 9(4):284-7. PubMed ID: 9112337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of high-dose immunoglobulin and cyclosporine in newly diagnosed diabetic children].
    Romanello C; Grossi F; Radillo L; Betterle C; Marinoni S; Agosti E; Pocecco M; Boehm P
    Pediatr Med Chir; 1991; 13(4):355-8. PubMed ID: 1754467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year.
    Moncada E; Subirá ML; Oleaga A; Goñi F; Sánchez-Ibarrola A; Monreal M; Sevilla M; Goñi MJ; Yoldi A; Terán D
    J Autoimmun; 1990 Oct; 3(5):625-38. PubMed ID: 2252531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
    Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
    Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes.
    Björk E; Berne C; Kämpe O; Wibell L; Oskarsson P; Karlsson FA
    Diabetes; 1996 Oct; 45(10):1427-30. PubMed ID: 8826981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deficiency of erythropoietin is not responsible for the anaemia associated with cyclosporin treatment of insulin-dependent diabetes mellitus. Canadian-European Randomized Control Trial Group.
    Nielsen OJ; Mandrup-Poulsen T; Nerup J
    J Intern Med; 1993 Jun; 233(6):471-6. PubMed ID: 8501418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phagocyte oxidative metabolism in cyclosporine- or placebo-treated patients with insulin-dependent (type I) diabetes mellitus of recent onset.
    Descamps-Latscha B; Nguyen AT; Feutren G
    J Autoimmun; 1990 Apr; 3(2):201-13. PubMed ID: 2187453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.
    Gabbay MA; Sato MN; Finazzo C; Duarte AJ; Dib SA
    Arch Pediatr Adolesc Med; 2012 Jul; 166(7):601-7. PubMed ID: 22751874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunosuppression with cyclosporin induces clinical remission and improved beta cell function in patients with newly diagnosed insulin-dependent diabetes. A national and international multicenter study].
    Mandrup-Poulsen TR; Mølvig JC; Andersen V; Bendtzen K; Binder C; Brøns M; d'Amore FA; Dieperink H; Enk B; Frandsen NE
    Ugeskr Laeger; 1990 Jul; 152(27):1963-9. PubMed ID: 2195734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus.
    Ohno Y; Aoki N; Nishimura A
    J Clin Endocrinol Metab; 1993 Oct; 77(4):1072-7. PubMed ID: 8408455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha.
    Pakala SV; Chivetta M; Kelly CB; Katz JD
    J Exp Med; 1999 Apr; 189(7):1053-62. PubMed ID: 10190896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy.
    Limb GA; Soomro H; Janikoun S; Hollifield RD; Shilling J
    Clin Exp Immunol; 1999 Mar; 115(3):409-14. PubMed ID: 10193411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.